Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss Manufacturing Chemist 3d
Biogen, Denali Discontinue BIIB122 Development In Idiopathic Parkinson’s After Phase IIb Miss Scrip Pharma Intelligence 6d
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss Manufacturing Chemist 3d Denali Biotech Pharma All sources
BIIB advances Alzheimer's disease drug despite study missing main goal Zacks 17:32 Fri, 15 May Pharma All sources
Italy probes Biogen for allegedly hindering sales of rival's MS drug The Tribune, California 1d Biotech Pharma
Tata-backed MedTherapy claims car-T breakthrough with one-day production The Times of India 19h Biotech
GLP-1 manufacturer CordenPharma strikes deal for peptide Cdmo, lining up new production sites in US and China FiercePharma 19h
Spruce Biosciences to participate in upcoming conferences in June Business Wire (Press Release) 14h Biotechnology
Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases PR Newswire (Press Release) 2d Biotechnology
